|invitae in the news||1.85||0.5||6381||63|
|invitae stock news||0.35||0.3||5791||70|
|invitae corporation news||1.12||0.6||5178||33|
|davita in the news||0.35||1||1262||100|
|invitae stock price today||1.11||0.8||6162||2|
|invitae insurance in network||0.3||0.3||8434||57|
|is invitae a buy||1.19||0.7||5690||29|
|invitae stock motley fool||0.87||0.8||8066||25|
|invitae corp stock forecast||1.4||0.8||6838||62|
|how much does invitae cost||1.21||0.8||1458||47|
|where is invitae located||0.55||0.1||3154||27|
|invitae corporation stock price||1.4||0.5||4909||47|
|why is invitae stock down||0.15||0.3||7718||100|
|invitae in network insurances||0.58||0.7||1145||54|
|invitae stock price forecast||0.41||0.8||8221||46|
|invitae corp stock price||1.55||1||3058||35|
|invitae stock price history||0.49||0.3||2102||100|
|what analysts are saying about invitae||0.32||0.7||8842||52|
|invitae board of directors||1.82||0.5||4343||95|
|invitae number of employees||1.43||0.4||2886||25|
|invitae australia pty ltd||0.33||0.8||40||88|
|what is invitae corporation||1.36||0.4||2067||8|
|invitae for healthcare providers||1.3||0.4||7691||79|
|what is invitae corp||1.53||0.9||2329||9|
|invitae corporation investor relations||1.65||0.7||5347||49|
The shares of Invitae Corporation ( NYSE: NVTA ) fell ~5% pre-market Tuesday after Goldman Sachs downgraded it to Sell from Neutral predicting a long path to profitability for the medical diagnostics company despite its recent efforts at restricting.Does Invitae have a long path to profitability?
Despite having a restricting plan in place, the biotech company has a “long path to profitability,” according to Goldman Sachs. The Analyst: Matthew Sykes downgraded the rating for Invitae from Neutral to Sell, while reducing the price target from $4 to $2. Check out other analyst stock ratings.Is Invitae poised to re-accelerate growth?
Invitae seems to have “a long and uncertain path towards profitability and a gross margin profile that will make it difficult to deploy opex in order to re-accelerate growth,” the analyst added.What is the target price for Invitae Corporation (NVTA)?
Invitae Corporation (NYSE:NVTA)’s beta value is holding at 1.86, while the average true range (ATR) indicator is currently reading 0.23. Considering analysts have assigned the stock a price target range of $1.00-$4.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $2.84.